Tourmaline Bio looks to raise cash through a public offering
https://seekingalpha.com/news/4058138-tourmaline-bio-looks-to-raise-cash-through-a-public-offering?source=feed_sector_healthcare
Jan 24, 2024 - Tourmaline Bio announces proposed public offering of common stock. Underwriters may purchase additional shares.
0
SPAC Semper Paratus shareholders okay merger with Tevogen Bio
https://seekingalpha.com/news/4061494-spac-semper-paratus-shareholders-okay-merger-with-tevogen-bio?source=feed_sector_healthcare
Feb 01, 2024 - SPAC Semper Paratus Acquisition Corp. (LGST) shareholders have approved a merger deal with immunotherapy developer Tevogen Bio (TVGN). Read more here.
0
Intelligent Bio Solutions Expects Higher Q2 Revenue, Stock Up In Pre-Market
https://www.rttnews.com/story.aspx?Id=3421577
Feb 02, 2024 - Medical technology company Intelligent Bio Solutions Inc. (INBS), Friday announced that it expects higher revenue for its second quarter. The preliminary outlook is mainly due to increased demand for its drug screening solution, and expansion into new global markets.
0
Entera Bio GAAP EPS of -$0.31 beats by $0.01
https://seekingalpha.com/news/4077759-entera-bio-gaap-eps-of-0_31-beats-0_01?source=feed_tag_israel
Mar 08, 2024 - Entera Bio beats expectations with FY 2023 GAAP EPS of -$0.31.
0
Oncology drug developer Boundless Bio files for $100M IPO
https://seekingalpha.com/news/4077787-oncology-drug-developer-boundless-bio-files-for-100m-ipo?source=feed_sector_healthcare
Mar 08, 2024 - Boundless Bio (BOLD), a developer of ecDNA-directed oncology therapeutics, has filed for a proposed $100M initial public offering. Read more here.
0
Boundless Bio Starts $100 Million U.S. IPO Plan
https://seekingalpha.com/article/4677702-boundless-bio-starts-100-million-us-ipo-plan?source=feed_tag_ipo_analysis
Mar 12, 2024 - Boundless Bio filed for $a 100M IPO to develop DNA treatments for cancer, and its lead candidate is in Phase 1 trials. Click here to learn more about BOLD.
0
2seventy bio appoints Eli Casdin and Charles Newton to its board of directors
https://seekingalpha.com/news/4081841-2seventy-bio-appoints-eli-casdin-and-charles-newton-to-its-board-of-directors?source=feed_sector_healthcare
Mar 20, 2024 - 2seventy bio (TSVT) announces the appointment of Eli Casdin and Charles Newton to its board of directors.
0
Bayer-backed Boundless Bio sets terms for $100M IPO
https://seekingalpha.com/news/4082227-bayer-back-boundless-bio-sets-terms-for-100m-ipo?source=feed_sector_healthcare
Mar 21, 2024 - Bayer-backed Boundless Bio (BOLD), an oncology drug developer, has set terms for a proposed $100M initial public offering. Read more here.
0
Mustang Bio stock climbs 9% amid drug development update
https://seekingalpha.com/news/4085033-mustang-bio-stock-climbs-amid-drug-development-update?source=feed_sector_healthcare
Mar 28, 2024 - Mustang Bio (MBIO) stock rose 9% Thursday after the company said it was planning to expand testing of its oncology drug candidate MB-106 into autoimmune diseases. Read more here.
0
Bayer-backed Boundless Bio sees stock fall 8% after $100M IPO
https://seekingalpha.com/news/4085101-bayer-backed-boundless-bio-stock-falls-after-100m-ipo?source=feed_sector_healthcare
Mar 28, 2024 - Bayer-backed Boundless Bio (BOLD) saw its shares drop 8% following a $100M initial public offering on Thursday. Read more here.
0